Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus

NEXT STORY
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
PREV STORY
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Life Science Reagents Market to exceed US$ 67.0 Bn by 2026, Says TMR

Life Science Reagents Market: Technological Advancements and High Prevalence of Chronic and Infectious Diseases ...

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

author_avatar
NASDAQ Market News

Eagle Hill School First to Use RxAir® UV Light Air Purifiers Campus-Wide to Combat Airborne Viruses

author_avatar
NASDAQ Market News